Apple picks up personal health data co. Gliimpse

apple store fifth avenue new york

Apple ($AAPL) has quietly acquired Gliimpse, a personal health data startup co-founded in 2013 by a former Apple systems engineer. While the deal took place earlier this year, Apple kept it under wraps, only confirming it this week, Fast Company reported.

"Apple buys smaller technology companies from time to time, and we generally do not discuss our purpose or plans,” Apple told the news outlet.

Redwood City, CA-based Gliimpse was founded on the premise that any American should be able to collect, personalize and share his or her health data. It touts its product as the first automated personal health data platform, where a series of computational algorithms enables users to collect data from “fragmented” sources into patient summaries and share it, thereby “unlocking hospital siloes.”

WEBINAR

Webinar: Meet the Challenge of Complex Protein Expression

As market demand continues to rise for more potent and effective therapeutics, biologic pipelines are evolving from standard antibody formats to next-generation biologics (NGBs). In this webinar we will discuss and demonstrate application through case studies, two significant enhancements to Lonza’s GS Xceed® expression system to help address the challenges of NGBs.

The platform could help hospitals comply with a new Centers for Medicare & Medicaid Services rule requiring that more than 10% of a hospital's patients engage with their electronic health record in some way, and that patient-generated health data be incorporated into the records of more than 5% of patients. The requirement will take effect next year. 

This acquisition is just the latest in a string of moves on the healthcare front. The tech giant has been steadily building its healthcare capabilities over the past year, most recently debuting emergency call and medical ID functions on its Apple Watch and recruiting Merck veteran and Sage Bionetworks founder, Dr. Stephen Friend, to take the lead on “health-related projects.”

Apple also launched ResearchKit, which provides a framework for the development of apps to collect data for research purposes, and CareKit, which helps patients manage their health electronically by tracking their symptoms and how often they take their medication.

As for the Apple Watch, which CEO Tim Cook billed as a potential “holy grail” in healthcare in May, the company has stumbled a little since its launch. Apple had to walk back some promises, such as the inclusion of a glucometer for diabetics, because the device would fall under FDA purview if it prompted people to make medical decisions based on its output.

- here's the Fast Company story

Related Articles:
Apple taps Merck veteran to take on 'health-related projects'
New Apple Watch OS debuts emergency call, medical ID functions
Apple Watch will become 'holy grail' in healthcare, Apple CEO says
Let's make a med tech deal: J&J, Medtronic, Apple, Google sit on piles of cash
Study: Fitness devices useful in orthopedic surgery--could offer means to placate CMS

Suggested Articles

J&J’s Ethicon unit received an FDA clearance for its Vistaseal applicators that spray a biologic sealant from Grifols to help stem surgical bleeding.

Gilead Sciences is paying Nurix $45 million upfront in a deal that could reach $2.3 billion in value if all milestones are met and royalties realized.

Bio-Techne’s urine test has received a breakthrough device designation from the FDA for ruling out unnecessary tissue biopsies.